搜尋結果
Today's Refinance Rates: June 13, 2024—Rates Dip
Forbes· 9 小時前The rate on a 30-year fixed refinance tumbled today. The average rate on a 30-year fixed ...
FDA advisors recommend Eli Lilly's Alzheimer's drug donanemab, paving way for approval
CNBC· 3 日前Eli Lilly & Co.'s shares climbed in early US trading after its experimental drug for ...
Alzheimer’s Disease Drug Donanemab Gets Unanimous Backing From FDA Expert Panel
Forbes· 3 日前The panel concluded that the therapeutic is effective in treating the memory-robbing condition ...
US Supreme Court bars 'Trump too small' trademark
Reuters· 5 小時前The U.S. Supreme Court barred on Thursday a federal trademark for the phrase "Trump Too ...
Stock handouts might help save the US ruling class
Reuters· 9 小時前The American dream now runs through the stock market. Although politicians are struggling to ...
Why FDA Panel Rejected MDMA Therapy—And What’s Next For Psychedelic Medicine
Forbes· 14 小時前High hopes that psychedelic medicines were finally on the pathway to regulation were dashed ...
Council Post: Employee Health And Wellness Programs Have Overlooked Brain Health: The Case For ...
Forbes· 14 小時前In the fast-paced world of business, where every decision can make or break a company's ...
Council Post: Growing Pains: Can Your Mid-Tier Firm Expand Without Selling Its Soul?
Forbes· 14 小時前Inevitably, middle-market accounting firms reach a seemingly binary crossroads: Scale up to ...
FDA Panel Unanimously Recommends Eli Lilly’s Alzheimer’s Drug
Forbes· 4 日前All of the panel’s 11 members endorsed donanemab—which data from a clinical trial suggests can ...
Patent decision offers new look at weighing of factors for discretionary denial by PTAB
Reuters· 1 日前A current case to watch at the Patent Trial and Appeal Board (PTAB) is Vivendum Product Solutions, Inc. v. Rotolight Ltd ...